Active protein C is an endogenous modulator of both coagulation and inflammation. Imbalanced activation of protein C may occur as a consequence of inflammatory cytokines. A decreased level of activated protein C in patients with sepsis has been implicated as having a key role in determining multi-organ impairment. 1 The availability of a recombinant form of humanactivated protein C led to a multi-center, randomized, double-blind, placebo-controlled trial in adults with severe sepsis (PROWESS trial). Publication of these results in 2001 raised the hopes of all physicians who had lost a patient to severe sepsis. 2 The trial showed that the use of Drotrecogin alfa activated (Drot AA) decreased mortality (19.4% reduction of the relative risk of death), but increased the risk of serious bleeding (3.5% in the treated group vs 2% in the placebo group, P ¼ 0.06). Pastores et al. 3 report on a phase-IV, open-label, clinical trial designed for hematopoietic stem cell transplant (HSCT) patients with severe sepsis. The primary end point was to investigate the safety of Drot AA in HSCT patients with severe sepsis assessed as the rate of intracranial hemorrhage and other severe bleeding. However, the authors were unable to complete the trial, which was stopped prematurely due to slow accrual (only seven patients enrolled in 10 months), when it became clear that achieving the study end points was not feasible.
Pediatric patients represent another group of patients for which the use of Drot AA is still unclear. The safety, pharmacokinetics and pharmacodynamics of Drot AA in children are reportedly comparable to those observed in adults. 4 Also, there are anecdotal reports of the use of Drot AA in children and neonates with severe sepsis. 5, 6 Although no exhaustive data on the therapeutic ratio of Drot AA in children are published, the high mortality rate related to severe sepsis induced us to use Drot AA in seven pediatric patients with cancer who met the criteria for severe sepsis, defined as sepsis with acute organ dysfunction. 7 The patients received Drot AA 24 mg/kg/h by continuous intravenous infusion for 96 h, in addition to standard care. Table 1 summarizes the main clinical characteristics and outcome of the patients. Although five of the seven children survived, the data do not allow us to draw conclusions on the efficacy of the drug. The most significant finding was the absence of minor or serious bleeding complications, despite a high prevalence of thrombocytopenia. As bleeding is the main concern with the use of Drot AA, Pastores et al. requested in their paper that other physicians report any observed bleeding episodes or other important side effects of the drug. Although it is not possible to affirm that this serious side effect is rare in children with cancer receiving Drot AA for severe sepsis, we were compelled to report our experience of lack of bleeding. Careful assessment of the risk/benefit ratio is mandatory before the introduction of 'new drugs' into clinical practice. Trials with end points of mortality in children with severe sepsis are very difficult to perform because of the lower rate of sepsis and sepsis-related mortality in this patient group. Many clinicians use as yet unproven medical interventions because they feel that the risk of waiting for clearcut evidence could result in loss of life. This occurs particularly in clinical settings such as sepsis in immune-suppressed patients, where the extreme severity of the condition gives the physician clinical and ethical authorization to use a drug whose safety/efficacy profile has not been clearly established. Pediatric oncologists often experience the frustration of controlling the malignancy, but loosing the cancer patient to sepsis. Such phenomena may lead to the so-called 'boomerang effect' frequently seen when new therapeutic agents, not carefully investigated, are available. 
